RxDoctor Payments Data

Syed Ali, MD

Internal Medicine · Mc Kees Rocks, PANPI 1144210766

Payments from drug & device makers

$236in general payments, 2019–2025

Across 14 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$75
  • Johnson & Johnson$73
  • Cook Medical LLC$25
  • AstraZeneca$19
  • United Therapeutics Corporation$16
  • GSK$16
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$236100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$236 in reported general payments places this provider in the 55th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$64,378
Medicare patients
260
Services billed
786

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate36$178,144
EliquisApixaban449$147,096
Trelegy ElliptaFluticasone/Umeclidin/Vilanter143$104,199
JardianceEmpagliflozin162$59,970
XareltoRivaroxaban125$54,903
JanuviaSitagliptin Phosphate33$34,838
TrulicityDulaglutide34$34,794
TradjentaLinagliptin67$31,376
OzempicSemaglutide28$27,941
EntrestoSacubitril/Valsartan67$25,641
RexultiBrexpiprazole32$23,527
Atorvastatin Calcium920$16,026
Breo ElliptaFluticasone/Vilanterol28$11,048
ArexvyRsvpref3 Antigen/As01e/Pf31$10,135
Lurasidone Hcl25$7,445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Anoro Ellipta$16$130,372213 claims
Johnson & JohnsonXarelto$73$54,903125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Mc Kees Rocks

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →